Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Werewolf Therapeutics Inc (HOWL)

Werewolf Therapeutics Inc (HOWL)
1.2300 -0.0100 (-0.81%) 03/07/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 1.2300 unch (unch) 16:02 ET
Quote Overview for Fri, Mar 7th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.2000
Day High
1.2900
Open 1.2200
Previous Close 1.2400 1.2400
Volume 146,300 146,300
Avg Vol 284,530 284,530
Stochastic %K 37.60% 37.60%
Weighted Alpha -81.32 -81.32
5-Day Change -0.0100 (-0.81%) -0.0100 (-0.81%)
52-Week Range 1.0300 - 7.0800 1.0300 - 7.0800
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,812
  • Shares Outstanding, K 44,563
  • Annual Sales, $ 19,940 K
  • Annual Income, $ -37,370 K
  • EBIT $ -58 M
  • EBITDA $ -57 M
  • 60-Month Beta 0.37
  • Price/Sales 15.02
  • Price/Cash Flow N/A
  • Price/Book 0.61

Options Overview Details

View History
  • Implied Volatility 290.92% ( -38.21%)
  • Historical Volatility 66.86%
  • IV Percentile 85%
  • IV Rank 33.19%
  • IV High 845.37% on 10/16/24
  • IV Low 15.47% on 10/15/24
  • Put/Call Vol Ratio 0.43
  • Today's Volume 33
  • Volume Avg (30-Day) 44
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 2,478
  • Open Int (30-Day) 2,220

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.43
  • Number of Estimates 5
  • High Estimate -0.22
  • Low Estimate -0.80
  • Prior Year -0.33
  • Growth Rate Est. (year over year) -30.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0300 +19.42%
on 03/04/25
Period Open: 1.3600
1.5997 -23.11%
on 02/13/25
-0.1300 (-9.56%)
since 02/07/25
3-Month
1.0300 +19.42%
on 03/04/25
Period Open: 1.8000
1.9450 -36.76%
on 12/09/24
-0.5700 (-31.67%)
since 12/06/24
52-Week
1.0300 +19.42%
on 03/04/25
Period Open: 6.7500
7.0800 -82.63%
on 03/08/24
-5.5200 (-81.78%)
since 03/07/24

Most Recent Stories

More News
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

HOWL : 1.2300 (-0.81%)
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

HOWL : 1.2300 (-0.81%)
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

HOWL : 1.2300 (-0.81%)
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

HOWL : 1.2300 (-0.81%)
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

HOWL : 1.2300 (-0.81%)
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

HOWL : 1.2300 (-0.81%)
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINEâ„¢ Molecule for Inflammatory Diseases

HOWL : 1.2300 (-0.81%)
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

HOWL : 1.2300 (-0.81%)
RSI Oversold: 2 Stocks (HOWL, WKHS) Potentially Signaling a Contrarian Buy

Sometimes equities that have been pushed too far down are at risk of surprisingly bouncing back.

HOWL : 1.2300 (-0.81%)
WKHS : 0.3478 (-1.50%)
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights

- FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for advanced solid tumors - - Submission of IND application for...

HOWL : 1.2300 (-0.81%)

Business Summary

Werewolf Therapeutics Inc. is a biopharmaceutical company. It involved in the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Werewolf Therapeutics Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 1.3700
2nd Resistance Point 1.3300
1st Resistance Point 1.2800
Last Price 1.2300
1st Support Level 1.1900
2nd Support Level 1.1500
3rd Support Level 1.1000

See More

52-Week High 7.0800
Fibonacci 61.8% 4.7689
Fibonacci 50% 4.0550
Fibonacci 38.2% 3.3411
Last Price 1.2300
52-Week Low 1.0300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
How to Trade Futures Spreads Like a Pro – Unlock Powerful Market Insights